Shows
VJHemOnc PodcastHighlights from iwMyeloma 2025: trial updates and practical considerationsVJHemOnc was delighted to be media partners for the 18th International Workshop on Multiple Myeloma (iwMyeloma), held in Miami, FL. This podcast episode features highlights from the meeting.
First, you will hear from Rafael Fonseca, MD, Mayo Clinic, Phoenix, AZ, Ola Landgren, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, Thomas Martin, MD, University of California San Francisco, San Francisco, CA, and Adriana Rossi, MD, Mount Sinai, New York City, NY, who share updates with the use of several agents in multiple myeloma. Damian Green, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL...2025-05-0235 minVJHemOnc PodcastUpdates to the ESMO CLL clinical practice guidelines: implications for frontline treatmentIn this VJHemOnc podcast, experts Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, Lydia Scarfò, MD, Vita-Salute San Raffaele University and IRCCS San Raffaele Scientific Institute, Milan, Italy, and Anna Schuh, MD, PhD, University of Oxford, Oxford, UK, provide insights into the latest updates to the ESMO clinical practice guidelines for chronic lymphocytic leukemia (CLL). They cover key topics such as diagnostic advancements, frontline treatment strategies based on IGHV mutational status, the role of double oral combinations, the importance of measurable residual disease (MRD)-guided treatment, and the debate between time-limited and continuous regimens.
The post Updates t...2025-04-2534 minVJHemOnc PodcastHighlights from EBMT 2025: preventing and managing GvHD, harnessing AI in transplant, & moreIn this week’s VJHemOnc podcast, we’ll be sharing highlights from the 51st Annual Meeting of the EBMT, with a focus on the prevention and management of graft-versus-host disease (GvHD) and infections associated with stem cell transplantation (SCT). You will also hear about the potential of artificial intelligence (AI) in hematology and transplantation.
Tune in as experts Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, and Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, provide insights into current treatment approaches for acute and chronic GvHD, discussing the advent of new therapies. Following this, you’ll hear a...2025-04-1722 minVJHemOnc PodcastPost-ASH amyloidosis highlights: the ANDROMEDA trial, risk stratification, value of MRD, & more!Today’s podcast features a discussion with experts Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, and Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM, University College London Hospitals NHS Foundation Trust, London, UK, from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. They share their key highlights in amyloidosis from the meeting, including updates from the ANDROMEDA trial (NCT03201965), the risk stratification of patients with light chain (AL) amyloidosis, the value of measurable residual disease (MRD), and potential advances with CAR T-cell therapy in this disease setting.
The post Post-ASH amyloidosis highlights: th...2025-02-2113 minVJHemOnc PodcastPost-ASH non-malignant highlights: updates in sickle cell disease, thalassemia, and hemophiliaThis episode of the VJHemOnc podcast covers updates in non-malignant hematological diseases from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, which took place in San Diego, CA. You will hear the latest updates in sickle cell disease (SCD), thalassemia, and hemophilia from leading experts.
First, Sophia Delicou, MD, Hippokration General Hospital, Athens, Greece, will provide an update on the HIBISCUS (NCT04624659) trial of etavopivat in SCD, and Rabi Hanna, MD, Cleveland Clinic, Cleveland, OH, will present updated results of the RUBY (NCT04853576) trial investigating reni-cel in severe SCD. This will be followed by...2025-02-1418 min
VJHemOnc PodcastPost-ASH non-malignant highlights: updates in sickle cell disease, thalassemia, and hemophiliaThis episode of the VJHemOnc podcast covers updates in non-malignant hematological diseases from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, which took place in San Diego, CA. You will hear the latest updates in sickle cell disease (SCD), thalassemia, and hemophilia from leading experts.
First, Sophia Delicou, MD, Hippokration General Hospital, Athens, Greece, will provide an update on the HIBISCUS (NCT04624659) trial of etavopivat in SCD, and Rabi Hanna, MD, Cleveland Clinic, Cleveland, OH, will present updated results of the RUBY (NCT04853576) trial investigating reni-cel in severe SCD. This will be followed by...2025-02-1418 minVJHemOnc PodcastPost-ASH myeloma highlights: key takeaways for community physicians & trials to look out for in 2025This podcast brings you exclusive updates on multiple myeloma from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, held in San Diego, CA. In this episode, experts Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, Rahul Banerjee, MD, FACP, Fred Hutchinson Cancer Center, Seattle, WA, Alexander Lesokhin, MD, Memorial Sloan Kettering Cancer Center, New York, NY, Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, Mansi Shah, MD, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center & University of Miami, Miami...2025-02-0618 minVJHemOnc PodcastPost-ASH AML highlights: novel approaches to frontline therapy, advances with menin inhibitors, & managing FLT3-ITD+ AMLIn this podcast, we bring you exclusive updates in acute myeloid leukemia (AML) from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, which took place in San Diego, CA.
You will hear insights into novel approaches to frontline chemotherapy and BCL2 inhibition from experts Ioannis Mantzaris, MD, Montefiore Medical Center/Albert Einstein College of Medicine, New York City, NY, Tapan Kadia, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Chong Chyn Chua, MBBS, FRACP, FRCPA, The Alfred Hospital and Monash University, Melbourne, Australia.
Eunice Wang, MD, Roswell Park...2025-01-3129 minVJHemOnc PodcastPost-ASH MPN highlights: key trial updates in MF, novel approaches being explored in R/R disease, & more!This podcast episode covers highlights in myeloproliferative neoplasms (MPNs) from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, which took place in San Diego, CA.
First, you will hear key trial updates in myelofibrosis (MF) from Andrew Kuykendall, MD, Moffitt Cancer Center, Tampa, FL, Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Francesco Passamonti, MD, University of Milan, Milan, Italy. Following this, Marina Kremyanskaya, MD, PhD, Icahn School of Medicine at Mount Sinai, New York, NY, will present initial results from the Phase I/II SANRECO trial (NCT05499013...2025-01-2822 minVJHemOnc PodcastPost-ASH NHL highlights: novel combinations in the frontline setting and advancements with immunotherapy in the R/R settingToday’s podcast showcases key updates in non-Hodgkin lymphoma (NHL) from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, which took place in San Diego, CA.
First, you will hear from Gilles Salles, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, Catherine Diefenbach, MD, NYU Langone, New York, NY, and Jia Ruan, MD, PhD, Weill Cornell Medical College, New York City, NY, who discuss novel combinations being explored in the frontline setting for diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). Sattva Neelapu, MD, The University of Texas MD Anderson Ca...2025-01-2431 minVJHemOnc PodcastPost-ASH MDS highlights: managing anemia in LR-MDS and novel approaches to treating HR-MDSThis podcast is the second episode in our series spotlighting key highlights from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, which took place in San Diego, CA. This episode focuses on updates in myelodysplastic syndromes (MDS).
You will hear insights into managing anemia in lower-risk MDS (LR-MDS) from Sophie Park, MD, CHU Grenoble Alpes, Grenoble, France, Esther Oliva, MD, Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio Calabria, Italy, and Uwe Platzbecker, MD, University of Leipzig, Leipzig, Germany. They share data from the EPO-Pretar trial (NCT03223961), which is investigating early versus late onset of...2025-01-1719 minVJHemOnc PodcastPost-ASH CLL highlights: BTK inhibitors & degraders, bispecific antibodies, & more!VJHemOnc recently attended the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA, where we gained expert insights into cutting-edge research in hematological malignancies. This podcast series will cover highlights in a variety of disease areas. Today’s episode focuses on chronic lymphocytic leukemia (CLL).
You will hear from experts Jeff Sharman, MD, Willamette Valley Cancer Institute, Eugene, OR, Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, Alexey Danilov, MD, PhD, City of Hope, Duarte, CA, Nirav Niranjan Shah, MD, Medical College of Wisconsin, Milwaukee, WI, and Chan Cheah, MBBS, FRACP, FR...2025-01-1016 minVJHemOnc PodcastPost-ASH CLL highlights: BTK inhibitors & degraders, bispecific antibodies, & more!VJHemOnc recently attended the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA, where we gained expert insights into cutting-edge research in hematological malignancies. This podcast series will cover highlights in a variety of disease areas. Today's episode focuses on chronic lymphocytic leukemia (CLL).
You will hear from experts Jeff Sharman, MD, Willamette Valley Cancer Institute, Eugene, OR, Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, Alexey Danilov, MD, PhD, City of Hope, Duarte, CA, Nirav Niranjan Shah, MD, Medical College of Wisconsin, Milwaukee, WI, and Chan Cheah, MBBS, FRACP, FRCPA, D...2025-01-1016 minVJHemOnc PodcastAdvancing treatment for BPDCN: current therapies, a deep dive into tagraxofusp, & emerging novel agentsBlastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy characterized by involvement of the skin, bone marrow, and lymph nodes, often associated with a poor prognosis. In this podcast episode, Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, provides an in-depth exploration of BPDCN. Dr Pemmaraju discusses the challenges in treating this disease and reviews current therapeutic options such as chemotherapy, tagraxofusp, and transplantation. He takes a deep dive into the CD123-targeted agent tagraxofusp, addressing patient eligibility, the role of tagraxofusp in bridging to transplantation, and real-world data on...2024-12-1828 minVJHemOnc PodcastImproving care for patients with SCD: pain management, ongoing projects & unmet needsThis week’s podcast focuses on strategies to improve care for patients with sickle cell disease (SCD), featuring expert insights from the 19th Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT 2024), which was held in London, UK. You will hear from Natasha Archer, MD, MPH, Harvard Medical School, Boston, MA, Subarna Chakravorty, MBBS, MRCPCH, FRCPath, PhD, King’s College Hospital NHS Trust, London, UK, Christiana Dinah, BSc, MBBS, MRes, London North West Healthcare NHS Trust, Harrow, UK, Leon Tshilolo, MD, PhD, Centre Hospitalier Monkole, Kinshasa, DR Congo, and Marsha Treadwell, PhD, University Of California San Francisco, San Francisco, CA...2024-12-0516 minVJHemOnc PodcastUnderstanding BPDCN: dermatology and hematology perspectives on presentation, diagnosis, treatment, & multidisciplinary careIn this podcast, experts Marlise Luskin, MD, MSCE, Dana-Farber Cancer Institute, Boston, MA, Nicole LeBoeuf, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, and Shai Shimony, MD, Dana-Farber Cancer Institute, Boston, MA, share insights into the clinical presentation, diagnosis, and treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare hematological malignancy. Dr Luskin and Dr Shimony provide insights from a hematology standpoint, while Dr LeBoeuf explores the diagnosis and pathogenesis of this rare disease through a dermatology perspective. The discussion covers pathology, patient demographics, the use of tagraxofusp and venetoclax, and the importance of collaboration within multidisciplinary teams.
2024-11-2834 minVJHemOnc PodcastManaging complications associated with WM: Bing-Neel syndrome, acquired von Willebrand disease, & more!Today’s podcast episode focuses on the management of complications associated with Waldenström’s macroglobulinemia (WM), featuring expert insights from the 12th International Workshop on Waldenström’s Macroglobulinemia (IWWM-12) held in Prague, Czech Republic. You will hear from Shirley D’Sa, MD, FRCP, FRCPath, University College London, London, UK, Monique Minnema, MD, PhD, University Medical Center Utrecht, Utrecht, Netherlands, and Jithma Abeykoon, MD, Mayo Clinic, Rochester, MN, who share advice on managing IgM demyelinating neuropathy, Bing-Neel syndrome, and acquired von Willebrand disease, respectively. Finally, Adam Sperling, MD, PhD, Dana Farber Cancer Institute, Boston, MA, speaks about clonal hematopoie...2024-11-1921 minVJHemOnc PodcastCAR-T therapies and bispecific antibodies in the treatment of high-risk multiple myeloma: updates from iwHRMM 2024This week’s podcast features discussions on the use of immunotherapy in the treatment of high-risk multiple myeloma (HRMM) from the 1st International Workshop on High-Risk Multiple Myeloma (iwHRMM), which took place Charleston, SC. You will hear from experts Ajai Chari, MD, University of California San Francisco, San Francisco, CA, and Krina Patel, MD, MSc, The University of Texas MD Anderson Cancer Center, Houston, TX, who discuss the use of CAR T-cells in the treatment of HRMM. They highlight clinical trial findings, the use of CAR-Ts in specific high-risk subgroups, and the potential for allogeneic CAR T-cell products. Additionally, Th...2024-11-1224 minVJHemOnc PodcastThe treatment landscape and challenges in rare diseases: BPDCN, CMML, MPN-AP/BP, and VEXASThis podcast features a discussion from the 6th International Workshop on Acute Leukemias (iwAL) 2024, which took place in Phoenix, AZ. You will hear from Anand Patel, MD, University of Chicago Medical Center, Chicago, IL, Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York City, NY, Guillermo Montalban-Bravo, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Emma Groarke, MD, National Institutes of Health, Bethesda, MD, who discuss several rare myeloid diseases, including accelerated- and blast-phase myeloproliferative neoplasms (MPN-AP/BP), blastic plasmacytoid dendritic cell neoplasm (BPDCN), chronic myelomonocytic leukemia (CMML), and VEXAS syndrome. The experts...2024-11-0622 minVJHemOnc PodcastExploring the role of BTK inhibitors in mantle cell lymphoma: sequencing & managing adverse eventsToday’s podcast focuses on the role of BTK inhibitors (BTKis) in the treatment of mantle cell lymphoma (MCL). You will hear from experts Krish Patel, MD, Providence Swedish Cancer Institute, Seattle, WA, Marek Trněný, MD, PhD, Charles University Hospital, Prague, Czech Republic, Michael Wang, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Craig Portell, MD, University of Virginia, Charlottesville, VA. They share updates on trials investigating BTKis in the frontline treatment of MCL, including the ECHO (NCT02972840), SHINE (NCT01776840), and TRIANGLE (NCT02858258) studies. They then go on to discuss how these agents are opti...2024-10-3009 minVJHemOnc PodcastAn update on menin inhibition in AML from iwAL 2024: current data, mechanisms of resistance, & more!Menin inhibitors are emerging as a promising therapeutic approach in acute myeloid leukemia (AML), particularly in patients with specific genetic mutations such as KMT2A-rearranged and NPM1-mutated AML. These inhibitors disrupt the leukemogenic signaling pathways that drive leukemia cell proliferation by blocking the actions of menin. They can help restore regular gene expression and halt the progression of AML.
In this podcast episode, you will hear updates on menin inhibitors in AML from the 6th International Workshop on Acute Leukemias (iwAL), which took place in Phoenix, AZ. Experts Joshua Zeidner, MD, UNC Lineberger Comprehensive Cancer Center...2024-10-2316 minVJHemOnc PodcastCAR T-cells and bispecific antibodies in the treatment of NHL: updates from iwNHL 2024Today’s podcast features discussions from the 21st International Workshop on Non-Hodgkin Lymphoma (iwNHL) which took place in Nice, France. You will hear updates on the use of CAR T-cell therapy in non-Hodgkin lymphoma (NHL) from experts Catherine Bollard, MBChB, MD, FRACP, FRCPA, Children’s National Health System, Washington, DC, Stephen Schuster, MD, University of Pennsylvania, Philadelphia, PA, and Jason Westin, MD, FACP, The University of Texas MD Anderson Cancer Center, Houston, TX. They discuss where CAR-T fits into the treatment landscape, managing toxicities, and the potential of allogeneic CAR-T products.
You will also hear from Stephen Anse...2024-10-1520 minVJHemOnc PodcastProlonging remission in AML: current approaches & future outlooksToday’s podcast features a discussion with leading experts Harry Erba, MD, PhD, Duke University, Durham, NC, Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, on strategies to prolong remission in acute myeloid leukemia (AML). They focus on the roles of intensive chemotherapy, allogeneic stem cell transplantation, and maintenance therapies. Key topics include optimizing initial therapy to achieve deeper remissions, the benefits of using measurable residual disease (MRD) assays to tailor post-remission treatments, and exploring new maintenance options such as targeted agents. ...2024-10-0831 minVJHemOnc PodcastA focus on the use of artificial intelligence to personalize blood cancer careWelcome to the final episode of VJHemOnc’s Blood Cancer Awareness Month special series!
This episode focuses on the role of artificial intelligence (AI) in personalizing blood cancer care. Carsten Niemann, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, discusses the value of AI in hematological oncology and how it is currently used in the clinic. He then shares details of a treatment infection model for chronic lymphocytic leukemia (CLL) that has been deployed in his institution. Gareth Morgan, MD, PhD, FRCP, FRCPath, NYU Langone, New York City, NY, delves into the role of AI in the classification of...2024-09-3028 minVJHemOnc PodcastA focus on the use of artificial intelligence to personalize blood cancer careWelcome to the final episode of VJHemOnc's Blood Cancer Awareness Month special series!
This episode focuses on the role of artificial intelligence (AI) in personalizing blood cancer care. Carsten Niemann, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, discusses the value of AI in hematological oncology and how it is currently used in the clinic. He then shares details of a treatment infection model for chronic lymphocytic leukemia (CLL) that has been deployed in his institution. Gareth Morgan, MD, PhD, FRCP, FRCPath, NYU Langone, New York City, NY, delves into the role of AI in the classification of m...2024-09-3028 minVJHemOnc PodcastA focus on pediatric leukemias: trials, treatments, & challengesWelcome to the third episode of VJHemOnc’s Blood Cancer Awareness Month special series!
The focus of this episode is pediatric acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). You will hear from Michele Redell, MD, Texas Children’s Cancer Center, Baylor College of Medicine, Houston, TX, who shares insights into the Pediatric Acute Leukemia (PedAL) Screening Trial and challenges that remain in the treatment of AML. Mark Litzow, MD, Mayo Clinic, Rochester, MN, discusses a study investigating drug responses in children compared to adults. Finally, Christina Peters, MD, St. Anna Children’s Hospital, Vienna, Austria, speaks...2024-09-2517 minVJHemOnc PodcastA focus on pediatric leukemias: trials, treatments, & challengesWelcome to the third episode of VJHemOnc’s Blood Cancer Awareness Month special series!
The focus of this episode is pediatric acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). You will hear from Michele Redell, MD, Texas Children’s Cancer Center, Baylor College of Medicine, Houston, TX, who shares insights into the Pediatric Acute Leukemia (PedAL) Screening Trial and challenges that remain in the treatment of AML. Mark Litzow, MD, Mayo Clinic, Rochester, MN, discusses a study investigating drug responses in children compared to adults. Christina Peters, MD, St. Anna Children’s Hospital, Vienna, Austria, speaks on the...2024-09-2517 minVJHemOnc PodcastA focus on the psychosocial impacts of living with blood cancerWelcome to the second episode of VJHemOnc’s Blood Cancer Awareness Month special series!
Today’s episode focuses on the psychosocial impacts of living with blood cancer. First, you will hear from Lorna Warwick, BA, Lymphoma Coalition, Toronto, Canada, who shares the work of the Lymphoma Coalition Global Patient Survey. Next, you will hear insights from Surabhi Chaturvedi, MBACP, King’s College Hospital NHS Foundation Trust, London, UK, who is a senior psychotherapist in hematological oncology. Finally, Charlie Craddock, CBE, FRCP, FRCPath, University of Birmingham, Birmingham, UK, will discuss the psychosocial impacts of transplantation in acute myeloid leukemi...2024-09-1836 minVJHemOnc PodcastA focus on the psychosocial impacts of living with blood cancerWelcome to the second episode of VJHemOnc’s Blood Cancer Awareness Month special series!
Today's episode focuses on the psychosocial impacts of living with blood cancer. First, you will hear from Lorna Warwick, BA, Lymphoma Coalition, Toronto, Canada, who shares the work of the Lymphoma Coalition Global Patient Survey. Next, you will hear insights from Surabhi Chaturvedi, MBACP, King’s College Hospital NHS Foundation Trust, London, UK, who is a senior psychotherapist in hematological oncology. Finally, Charlie Craddock, CBE, FRCP, FRCPath, University of Birmingham, Birmingham, UK, will discuss the psychosocial impacts of transplantation in acute myeloid leukemia (AML...2024-09-1836 minVJHemOnc PodcastGlobal perspectives on blood cancers: addressing disparities in awareness, diagnosis, and treatmentWelcome to the first episode of VJHemOnc’s Blood Cancer Awareness Month special series!
This episode focuses on global perspectives of blood cancers and addresses the disparities that exist in awareness, diagnosis, and treatment. First, Lalit Kumar, MD, MBBS, Artemis Hospital, New Delhi, India, discusses challenges that exist in the management of blood cancers in India, and programs that are in place to address these. Joseph Mikhael, MD, MEd, FRCPC, FACP, Translational Genomics Research Institute (TGen), Phoenix, AZ, then goes on to address racial disparities in the treatment of multiple myeloma in America. Amrutha Sridhar, MBBS, University Col...2024-09-0918 minVJHemOnc PodcastGlobal perspectives on blood cancers: addressing disparities in awareness, diagnosis, and treatmentWelcome to the first episode of VJHemOnc's Blood Cancer Awareness Month special series!
This episode focuses on global perspectives of blood cancers and addresses the disparities that exist in awareness, diagnosis, and treatment. First, Lalit Kumar, MD, MBBS, Artemis Hospital, New Delhi, India, discusses challenges that exist in the management of blood cancers in India, and programs that are in place to address these. Joseph Mikhael, MD, MEd, FRCPC, FACP, Translational Genomics Research Institute (TGen), Phoenix, AZ, then goes on to address racial disparities in the treatment of multiple myeloma in America. Amrutha Sridhar, MBBS, University College L...2024-09-0918 minVJHemOnc PodcastInsights into PV and ET: treating the AYA population, defining goals when treating patients, & morePolycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms (MPNs) characterized by the overproduction of red blood cells and platelets, respectively, due to mutations in hematopoietic stem cells.
This podcast features a discussion from the 2nd International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPNs). Experts Andrew Kuykendall, MD, Moffitt Cancer Center, Tampa, FL; Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX; and Kristen Pettit, MD, University of Michigan, Ann Arbor, MI, share insights into the management of PV and ET. They focus on treating the adolescent and young adult (AYA...2024-09-0211 minVJHemOnc PodcastHemophilia updates from ISTH 2024: ongoing clinical trials, emerging gene therapies & remaining challengesThis week’s VJHemOnc podcast brings you updates in hemophilia from the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH), held in Bangkok, Thailand, and virtually.
You hear from experts Omolade Awodu, MBChB, MD, FMCPath, University of Benin, Benin City, Nigeria, who discusses key hemophilia clinical trials in 2024, Radek Kaczmarek, PhD, Indiana University School of Medicine, Indianapolis, IN, who gives an overview of gene therapies for hemophilia, and Matteo Luciani, MD, Bambino Gesù Children’s Hospital, Rome, Italy, who shares insights into the remaining challenges for patients with hemophilia.
The post Hemophilia update...2024-08-1918 minVJHemOnc PodcastHemophilia updates from ISTH 2024: ongoing clinical trials, emerging gene therapies & remaining challengesThis week's VJHemOnc podcast brings you updates in hemophilia from the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH), held in Bangkok, Thailand, and virtually.
You hear from experts Omolade Awodu, MBChB, MD, FMCPath, University of Benin, Benin City, Nigeria, who discusses key hemophilia clinical trials in 2024, Radek Kaczmarek, PhD, Indiana University School of Medicine, Indianapolis, IN, who gives an overview of gene therapies for hemophilia, and Matteo Luciani, MD, Bambino Gesù Children’s Hospital, Rome, Italy, who shares insights into the remaining challenges for patients with hemophilia.
2024-08-1918 minVJHemOnc PodcastInflammation and immune interventions in MDS: targeting STAT, IRAK4, & moreIn myelodysplastic syndromes (MDS), chronic inflammation driven by the innate immune system plays a key role in disease progression. Signal Transducer and Activator of Transcription (STAT) and Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) are critical mediators in this process, where dysregulated signaling leads to aberrant hematopoiesis and the promotion of a pro-inflammatory environment that supports the clonal expansion of malignant cells.
This podcast episode features experts Andrew Wei, MBBS, PhD, Alfred Hospital and Monash University, Melbourne, Australia, Aditi Shastri, MD, Montefiore Medical Center, Bronx, NY, Uwe Platzbecker, MD, University of Leipzig, Leipzig, Germany, and Amer Zeidan, MBBS, Yale University...2024-08-1217 minVJHemOnc PodcastUpdates in the treatment of SCD and thalassemia from EHA 2024: key trial updates, challenges with gene therapies & unmet needsToday’s VJHemOnc podcast features experts Rabi Hanna, MD, The Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, Subarna Chakravorty, MBBS, MRCPCH, FRCPath, PhD, King’s College Hospital NHS Foundation Trust, London, UK, and Ali Taher, MD, PhD, FRCP, American University of Beirut Medical Center, Beirut, Lebanon. They discuss key updates in sickle cell disease (SCD) and thalassemia from the 29th Congress of the European Hematology Association (EHA), held in Madrid, Spain.
The experts share key trial updates, including the Phase I/II RUBY trial (NCT04853576) of renizgamglogene autogedtemcel (reni-cel) for SCD, and the Phase III ENERGIZE trial (NCT0...2024-08-0511 minVJHemOnc PodcastUpdates in the treatment of SCD and thalassemia from EHA 2024: key trial updates, challenges with gene therapies & unmet needsToday’s VJHemOnc podcast features experts Rabi Hanna, MD, The Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, Subarna Chakravorty, MBBS, MRCPCH, FRCPath, PhD, King’s College Hospital NHS Foundation Trust, London, UK, and Ali Taher, MD, PhD, FRCP, American University of Beirut Medical Center, Beirut, Lebanon. They discuss key updates in sickle cell disease (SCD) and thalassemia from the 29th Congress of the European Hematology Association (EHA), held in Madrid, Spain.
The experts share key trial updates, including the Phase I/II RUBY trial (NCT04853576) of renizgamglogene autogedtemcel (reni-cel) for SCD, and the Phase III ENERG...2024-08-0511 minVJHemOnc PodcastUnmet treatment needs in MF: managing prefibrotic disease & thrombocytopenia, novel agents & endpoints for clinical trialsMyelofibrosis (MF) is a chronic myeloproliferative neoplasm (MPN) characterized by bone marrow fibrosis, extramedullary hematopoiesis, and splenomegaly, often resulting in anemia and thrombocytopenia. There are many unmet treatment needs that remain in this space.
This week’s podcast features a discussion from the International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS / iwMPN 2024) held in Boston, MA. You will hear from Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Abdulraheem Yacoub, MD, The University of Kansas, Westwood, KS, Aaron Gerds, MD, MS, Cleveland Clinic, Cleveland, OH, and Claire Harrison, MD, FRCP, FRCPath, Guy’s...2024-07-2916 minVJHemOnc PodcastThe role of BTK inhibitors in MCL, ongoing trials & future outlooks: updates from EHA 2024The introduction of Bruton’s tyrosine kinase (BTK) inhibitors into the treatment landscape for mantle cell lymphoma (MCL) has transformed the field and provided patients with a promising therapeutic option. In this podcast, you will hear from leading experts who discuss the value of these agents in MCL, sharing updates from EHA 2024.
Tune in as Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, Tycel Phillips, MD, City of Hope, Duarte, CA, Chan Cheah, MBBS, Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia, and Alexey Danilov, MD, PhD, City of Hope, Duarte, CA, share in...2024-07-2212 minVJHemOnc PodcastNovel developments in lower-risk MDS & important practical considerations when treating patientsIn today’s VJHemOnc podcast, we will be sharing novel developments in lower-risk myelodysplastic syndromes (LR-MDS) and important practical considerations when treating patients.
You will hear from experts Amer Zeidan, MBBS, Yale University and Yale Cancer Center, New Haven, CT, Rena Buckstein, MD, FRCPC, Odette Cancer Research Program, Sunnybrook Research Institute, Toronto, Canada, Guillermo Garcia-Manero, MD, University of Texas MD Anderson Cancer Center, Houston, TX, and Andrew Brunner, MD, Massachusetts General Hospital, Boston, MA. They discuss important considerations for physicians when treating LR-MDS, providing valuable insights into some of the common pitfalls in clinical practice which may lead to...2024-07-1551 minVJHemOnc PodcastNovel developments in lower-risk MDS & important practical considerations when treating patientsIn today’s VJHemOnc podcast, we will be sharing novel developments in lower-risk myelodysplastic syndromes (LR-MDS) and important practical considerations when treating patients.
You will hear from experts Amer Zeidan, MBBS, Yale University and Yale Cancer Center, New Haven, CT, Rena Buckstein, MD, FRCPC, Odette Cancer Research Program, Sunnybrook Research Institute, Toronto, Canada, Guillermo Garcia-Manero, MD, University of Texas MD Anderson Cancer Center, Houston, TX, and Andrew Brunner, MD, Massachusetts General Hospital, Boston, MA. They discuss important considerations for physicians when treating LR-MDS, providing valuable insights into some of the common pitfalls in clinical practice which may lead to...2024-07-1551 minVJHemOnc PodcastUpdates on the use of BCMA-targeting bispecific antibodies in R/R multiple myeloma: insights from EHA & ASCO 2024BCMA-targeting bispecific antibodies treat multiple myeloma by binding to BCMA on malignant plasma cells and directing T-cells to initiate targeted cell killing. This podcast provides updates on the use of BCMA-targeting bispecific antibodies in relapsed/refractory (R/R) multiple myeloma from the 2024 American Society of Clinical Oncology (ASCO) Meeting and the 29th Congress of the European Hematology Association (EHA).
You will hear from Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, who discusses updated data from the MagnetisMM-3 trial (NCT04649359) of elranatamab and real-world findings from a French compassionate use program using this agent. Rahul Banerjee, MD...2024-07-0816 minVJHemOnc PodcastUpdates in the treatment of CLL from EHA 2024: BTK and BCL2 inhibitor combinations, BTK degraders, and moreIn today’s VJHemOnc podcast, we will be sharing key updates in the treatment of chronic lymphocytic leukemia (CLL) and Richter’s transformation (RT) from the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
You will hear from experts Toby Eyre, MBChB (Hons), DipMedEd, MRCP (UK), FRCPath (UK), MD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, and Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, who will discuss combinations of BTK and BCL2 inhibitors, the efficacy of BTK degraders in CLL, and the role of epcoritamab in the t...2024-07-0112 minVJHemOnc PodcastUpdates in the treatment of CLL from EHA 2024: BTK and BCL2 inhibitor combinations, BTK degraders, and moreIn today's VJHemOnc podcast, we will be sharing key updates in the treatment of chronic lymphocytic leukemia (CLL) and Richter’s transformation (RT) from the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
You will hear from experts Toby Eyre, MBChB (Hons), DipMedEd, MRCP (UK), FRCPath (UK), MD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, and Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, who will discuss combinations of BTK and BCL2 inhibitors, the efficacy of BTK degraders in CLL, and the role of epcoritamab in t...2024-07-0112 minVJHemOnc PodcastHighlights from ISA 2024: the importance of early diagnosis in AL amyloidosis, trials in progress & patient selection for SCTWelcome to today’s VJHemOnc podcast episode, where we will be sharing key highlights from the 2024 International Symposium on Amyloidosis (ISA), which was held in Rochester, MN. This podcast covers a variety of unmet needs in light chain (AL) amyloidosis, as well as emerging trials in the field.
Join leading experts Mario Nuvolone, MD, PhD, University of Pavia, Pavia, Italy, Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, Patrick Hagen, MD, Loyola University Medical Center, Chicago, IL, and Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, as they discuss the critical importance of...2024-06-2508 minVJHemOnc PodcastHighlights from ISA 2024: the importance of early diagnosis in AL amyloidosis, trials in progress & patient selection for SCTWelcome to today's VJHemOnc podcast episode, where we will be sharing key highlights from the 2024 International Symposium on Amyloidosis (ISA), which was held in Rochester, MN. This podcast covers a variety of unmet needs in light chain (AL) amyloidosis, as well as emerging trials in the field.
Join leading experts Mario Nuvolone, MD, PhD, University of Pavia, Pavia, Italy, Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, Patrick Hagen, MD, Loyola University Medical Center, Chicago, IL, and Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, as they discuss the critical importance of...2024-06-2508 minVJHemOnc PodcastTreating LR-MDS beyond ESA failure: currently approved agents, novel approaches & future outlooksWhile there have been advances in the treatment of lower-risk myelodysplastic syndromes (LR-MDS) in recent years, one major challenge that remains is the treatment of patients following the failure of erythropoiesis-stimulating agents (ESAs).
In this podcast, experts Amer Zeidan, MBBS, Yale Cancer Center, New Haven, CT, Valeria Santini, MD, University of Florence, Florence, Italy, and Courtney DiNardo, MD, MSCE, The University of Texas MD Anderson Cancer Center, Houston, TX, delve into the historical context of treatment developments, sharing insights on the emergence of novel agents like luspatercept and imetelstat. They explore the current paradigm for managing LR-MDS...2024-06-1146 minVJHemOnc PodcastBPDCN treatment and management: CD123-targeting agents, CNS involvement & approaching pediatric/AYA patientsBlastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic malignancy originating from plasmacytoid dendritic cells, characterized by skin lesions and frequent involvement of bone marrow and lymphoid tissues. Patients have a poor prognosis, making early diagnosis and advanced treatments, including targeted therapies, crucial for improving outcomes.
In this podcast, Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York City, NY, and Emanuele Angelucci, MD, Armando Businco Oncology Hospital, Sardegna, Italy, discuss the treatment and monitoring of BPDCN. They highlight the role...2024-06-0334 minVJHemOnc PodcastThe future of CAR-T therapy in lymphoma, addressing the risk of secondary malignancy & the optimal sequencing of these agents with bispecific antibodiesImmunotherapeutic approaches, including CAR T-cells and bispecific antibodies, have become well-established in later lines of non-Hodgkin lymphoma (NHL) treatment. CAR T-cells are engineered to target specific antigens expressed on lymphoma cells, and bispecific antibodies simultaneously bind to both tumor cells and immune cells, enhancing the immune response against NHL.
This podcast features experts Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, who discusses the future of CAR-T therapy and the risk of secondary malignancies, and Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, who gives an overview of the...2024-05-1612 minVJHemOnc PodcastiwMyeloma 2024 Session I: approaching bone disease, clinical trial updates & the value of MRD as an endpoint in trialsThe 17th International Workshop on Multiple Myeloma (iwMyeloma 2024) was held recently in Miami, FL, and brought together experts from around the world to discuss the latest updates, challenges, and research in the field.
In this episode, Ola Landgren, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, Suzanne Lentzsch, MD, PhD, Columbia University, New York, NY, Thomas Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, and Suzanne Trudel, MSc, MD, Princess Margaret Cancer Centre, Toronto, Canada, discuss the use of various agents in myeloma, including the suitability of bisphosphonates to treat bone d...2024-05-1027 minVJHemOnc PodcastManaging anemia in MF, key emerging trials in the UK, and approaching young patients with MPNsMyelofibrosis (MF) is a hematologic malignancy that causes progressive bone marrow fibrosis and presents with other clinical manifestations, including anemia and splenomegaly. MF-related anemia can be challenging to manage, and strategies are being explored to improve outcomes for patients.
Today’s VJHemOnc podcast features experts Mary Frances McMullin, MD, Queen’s University, Belfast, UK, who discusses strategies to manage anemia in MF, and Claire Harrison, MD, FRCP, FRCPath, Guy’s & St Thomas’ NHS Foundation Trust, London, UK, who gives a comprehensive overview of promising MPN clinical trials in the UK, and further discusses how to approach young patients...2024-05-0311 minVJHemOnc PodcastManaging anemia in MF, key emerging trials in the UK, and approaching young patients with MPNsMyelofibrosis (MF) is a hematologic malignancy that causes progressive bone marrow fibrosis and presents with other clinical manifestations, including anemia and splenomegaly. MF-related anemia can be challenging to manage, and strategies are being explored to improve outcomes for patients.
Today's VJHemOnc podcast features experts Mary Frances McMullin, MD, Queen’s University, Belfast, UK, who discusses strategies to manage anemia in MF, and Claire Harrison, MD, FRCP, FRCPath, Guy’s & St Thomas’ NHS Foundation Trust, London, UK, who gives a comprehensive overview of promising MPN clinical trials in the UK, and further discusses how to approach young patients with M...2024-05-0311 minVJHemOnc PodcastHighlights from EBMT 2024: treating & managing GvHD & understanding the role of the gut microbiomeGraft-versus-host disease (GvHD) is a common complication following allogeneic stem cell transplantation (alloSCT), which is typically classified as acute or chronic. In this week’s VJHemOnc podcast, we’ll be sharing key highlights from the 50th Annual Meeting of the EBMT, drawing focus on the biology and treatment of GvHD.
Tune in as experts Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, Ernst Holler, MD, University Hospital Regensburg, Regensburg, Germany, and Florent Malard, MD, PhD, Saint-Antoine Hospital and Sorbonne University, Paris, France, provide insights into current and emerging treatment approaches for acute and chronic GvHD, discussing the adven...2024-04-2622 minVJHemOnc PodcastHighlights from EBMT 2024: treating & managing GvHD & understanding the role of the gut microbiomeGraft-versus-host disease (GvHD) is a common complication following allogeneic stem cell transplantation (alloSCT), which is typically classified as acute or chronic. In this week's VJHemOnc podcast, we'll be sharing key highlights from the 50th Annual Meeting of the EBMT, drawing focus on the biology and treatment of GvHD.
Tune in as experts Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, Ernst Holler, MD, University Hospital Regensburg, Regensburg, Germany, and Florent Malard, MD, PhD, Saint-Antoine Hospital and Sorbonne University, Paris, France, provide insights into current and emerging treatment approaches for acute and chronic GvHD, discussing the advent of n...2024-04-2622 minVJHemOnc PodcastThe importance of cardio-oncology: awareness around the ESC 2022 guidelines & the value of building MDTsIn recent years, there has been great emphasis placed on the importance of cardio-oncology, with both cardiologists and hematologists highlighting the value of collaboration between specialists when treating patients with hematological malignancies. Furthermore, the 2022 European Society of Cardiology (ESC) cardio-oncology guidelines aim to help healthcare professionals with the treatment and management of cancer therapy-related cardiovascular toxicities (CTR-CVT).
In this podcast, Daniel Lenihan, MD, FACC, Saint Francis Healthcare System, Cape Girardeau, MO, Raul Cordoba, MD, PhD, University Hospital Fundación Jiménez Díaz, Madrid, Spain, and Iskra Pusic, MD, MSCI, Washington University School of Medicine, St. Louis, MO...2024-04-1143 minVJHemOnc PodcastExploring the possibility of early interception in smoldering myeloma: novel agents, challenges & advances in risk stratificationSmoldering multiple myeloma (SMM) and monoclonal gammopathy of undetermined significance (MGUS) are two well-known precursor conditions to multiple myeloma, and the possibility of early interception is a growing area of interest in the field.
In this week’s podcast, you will hear from Shaji Kumar, MD, Mayo Clinic, Rochester, MN, Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, and Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, who discuss novel technologies being explored to risk stratify individuals with SMM and MGUS. Following this, Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, Kwee Yong, PhD, FRCP, FRCPath, Univ...2024-04-0422 minVJHemOnc PodcastCHIP & CCUS: knowledge gaps, ongoing trials & recommendations for approaching patients with myeloid precursorsClonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of unknown significance (CCUS) are considered precursor diseases to hematologic malignancies, indicating early stages of blood disorders that may progress to more serious conditions such as leukemia or myelodysplastic syndromes (MDS).
In this podcast, Uma Borate, MD, The Ohio State University, Columbus, OH, Kelly Bolton, MD, PhD, Washington University School of Medicine, St. Louis, MO, and Eric Padron, MD, Moffitt Cancer Center, Tampa, FL, discuss knowledge gaps in the field, share insights from ongoing trials, and further emphasize the importance of multidisciplinary teamwork in managing CHIP and CCUS...2024-03-2813 minVJHemOnc PodcastMonoclonal B-cell lymphocytosis: classification, biology and exploring the possibility of early interceptionMonoclonal B-cell lymphocytosis (MBL) is a condition characterized by the presence of an abnormal increase in B lymphocytes in the blood. MBL is considered a precursor condition to chronic lymphocytic leukemia (CLL); however, not all cases of MBL progress to CLL, and many individuals with MBL do not require treatment.
In this podcast, Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, Paolo Ghia, MD, Vita-Salute San Raffaele University, Milan, Italy, Andrew Rawstron, PhD, Leeds Teaching Hospitals NHS Trust, Leeds, UK, and Anton Langerak, MD, PhD, Erasmus Medical Center and University, Rotterdam, The Netherlands, discuss the biology, classification...2024-03-2209 minVJHemOnc PodcastThe impact of CAR-T therapy on the myeloma treatment landscape, patient selection for CAR-T & the evolving role of autoSCTThe introduction of CAR-T therapy has revolutionized the myeloma treatment landscape, offering a promising therapeutic approach for patients with relapsed/refractory (R/R) disease. There are currently two approved CAR-T cells in multiple myeloma: idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), with ongoing studies exploring the possibility of bringing these agents into earlier lines of treatment.
In this podcast, Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, and Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discuss the significance of CAR-T therapy in m...2024-03-1513 minVJHemOnc PodcastDiagnosing amyloidosis, currently available therapies & the importance of cardio-oncologyWhile there have been advances in the treatment and management of amyloidosis in recent years, diagnosis remains a challenge due to the highly varied presentation of this disease. As clinicians and researchers work to improve outcomes for patients, there is increasing importance being placed on the role of the multidisciplinary team in treating these patients.
In this podcast, you will hear from Morie Gertz, MD, MACP, Mayo Clinic, Rochester, MN, Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM, University College London Hospitals NHS Foundation Trust, London, UK, and Daniel Lenihan, MD, FACC, Saint Francis Health System, Cape Girardeau...2024-03-0733 minVJHemOnc PodcastAddressing the importance of lymphodepletion, factors contributing to ICAHT & the cost effectiveness of CAR-T therapyAlthough CAR-T cells have revolutionized the treatment of hematological malignancies, there are several important factors that must be addressed regarding the use of these agents. One ongoing challenge is the prevention and management of CAR-T-related toxicities, including immune effector cell-associated hematotoxicity (ICAHT), as well as how to improve affordability and access to these agents.
In this podcast, you will hear from Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, who discusses the importance of lymphodepletion in CAR-T therapy, Kai Rejeski, MD, Memorial Sloan Kettering Cancer Center, New York, NY, who updates us on ICAHT, and G...2024-02-2913 minVJHemOnc PodcastUpdates with the use of CAR-T therapy in ALL: ongoing challenges, strategies to overcome resistance & future outlooksThe treatment landscape of acute lymphoblastic leukemia (ALL) has transformed with the introduction of novel immunotherapeutic agents, including CAR-T cells and antibody-based therapies. Despite these advances, several challenges remain in the field. In today’s episode, you will hear the latest updates with the use of CAR-T therapy in ALL, as discussed by renowned experts during the EBMT-EHA 6th European CAR T-cell meeting.
In this podcast, André Baruchel, MD, PhD, Hospital Robert Debré AP-HP, Paris, France, Pere Barba, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain, and Alex Rampotas, MD, University College London, London, UK, cover severa...2024-02-2212 minVJHemOnc PodcastTargeted therapy in AML: the growing role of menin inhibitors & clinical trials exploring these agentsThe treatment landscape of acute myeloid leukemia (AML) has transformed in recent years with the introduction of novel targeted agents, including FLT3 inhibitors, IDH inhibitors, and menin inhibitors. Menin inhibitors are currently being explored in several clinical trials, both as monotherapy and in combination with other agents.
In this podcast, Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, Ghayas Issa, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Ibrahim Aldoss, MD, City of Hope, Duarte, CA, and Aaron Goldberg, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY, comment on the...2024-02-1612 minVJHemOnc PodcastUpdates in lower- and higher-risk MDS: challenges, novel agents & key clinical trials at ASH 2023Myelodysplastic syndromes (MDS) are a heterogeneous group of hematologic neoplasms which can be categorized into lower- and higher-risk disease (LR-MDS; HR-MDS). Treatment and management strategies vary for LR-MDS versus HR-MDS, and a number of challenges remain in the field.
In this podcast, you will hear from leading experts who discuss several topics in LR-MDS and HR-MDS. Rena Buckstein, MD, FRCPC, Sunnybrook Research Institute, Toronto, Canada, and Valeria Santini, MD, University of Florence, Florence, Italy, discuss challenges in LR-MDS, including red blood cell transfusion dependence and approaching patients who fail erythropoiesis‑stimulating agents (ESAs). You will also hear fr...2024-02-0818 minVJHemOnc PodcastKey updates in thalassemia at ASH 2023: gene therapies, ongoing trials & the value of precision medicineIn the last decade, the treatment landscape of thalassemia has been transformed with the introduction of novel therapies. With several agents being evaluated in clinical trials, the future looks promising for patients. Despite these advances, there are challenges and unmet needs which remain, and both clinicians and researchers are working to address these, with the goal of improving outcomes for patients.
In this podcast, you will hear from experts Maria Domenica Cappellini, MD, University of Milan, Milan, Italy, and Kevin Kuo, MD, MSc, FRCPC, University Health Network, Toronto, Canada, who discuss recent updates in thalassemia presented at...2024-01-3112 minVJHemOnc PodcastUpdates, challenges and novel agents being explored in BPDCNBlastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive and rare hematological malignancy associated with poor prognosis. Several challenges remain in the diagnosis, treatment and management of this disease, with a lack of clinical trials in the field. However, clinicians and researchers are working to improve upon these unmet needs, with novel therapies being investigated.
In this podcast, you will hear from Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Nerses Ghahramanyan, MD, Yeolyan Hematology and Oncology Center, Yerevan, Armenia, Marco Herling, MD, University of Leipzig, Leipzig, Germany, and Claudio Cerchione, MD...2024-01-2509 minVJHemOnc PodcastUnanswered questions regarding the sequencing of BCMA therapies, the prognostic value of CTCs & the growing role of quadrupletsThe treatment and management of patients with multiple myeloma is continually evolving, giving rise to novel prognostic tools and therapeutic options, with associated benefits and challenges. Several ongoing clinical trials in the field are investigating potential treatment approaches and addressing many unanswered questions.
In this podcast, Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, and Benjamin Derman, MD, University of Chicago, Chicago, IL, discuss several interesting topics in myeloma, including the challenges associated with sequencing anti-BCMA therapies, the prognostic value of circulating tumor cells (CTCs), and the growing role...2024-01-1818 minVJHemOnc PodcastKey updates in sickle cell disease at ASH 2023: disease biology, ongoing trials & the growing role of gene therapyIn recent years, the treatment landscape of sickle cell disease (SCD) has been revolutionized with the introduction of novel agents, including recently approved gene therapies. There are several ongoing trials evaluating the safety of these agents in patients, with promising results being demonstrated.
In this podcast, leading experts Rabi Hanna, MD, Cleveland Clinic, Cleveland, OH, and Josu de la Fuente, PhD, FRCP, FRCPI, FRCPCH, FRCPath, Imperial College London, London, UK, discuss key updates in SCD presented at the 2023 ASH Annual Meeting and Exposition. The experts cover several topics, including the pathogenesis of SCD, novel agents being explored...2024-01-1211 minVJHemOnc PodcastASH 2023 highlights: updates in the diagnosis and treatment of amyloidosisIn recent years, the treatment and management of light chain (AL) amyloidosis has transformed with the introduction of novel agents. While diagnosis and risk stratification remain a challenge, clinicians and researchers are working to improve upon these. Furthermore, novel immunotherapies are being explored in the field, providing hope for patients.
In this podcast, you will hear from experts Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM, University College London Hospitals NHS Foundation Trust, London, UK, and Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, who discuss the latest updates in the treatment and management of AL...2024-01-0510 minVJHemOnc PodcastMPN highlights at ASH 2023: novel agents & ongoing clinical trials in ET, PV and MFThe treatment of the BCR-ABL1-negative myeloproliferative neoplasms (MPNs), including myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET), has transformed in recent years. Several clinical trials are exploring the safety and efficacy of novel agents and combinations, with promising advances being made.
At the 65th ASH Annual Meeting and Exposition, leading experts Ruben Mesa, MD, Levine Cancer Institute, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, NC, Claire Harrison, MD, FRCP, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, and Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, shar...2023-12-2217 minVJHemOnc PodcastiwNHL 2023 Session V: Expanding the CAR platform in NHLThe 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as they discussed the latest clinical updates in the field. In this podcast series, you will hear the latest advances in the treatment and management of lymphoma and gain an insight into the sessions that took place at this year’s meeting.
In this podcast, David Maloney, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA, Jason Westin, MD, FACP, The University of Texas MD Anderson Cancer Center, Houston, TX, and David Miklos, MD, PhD, Stanford University, Stanford, CA, di...2023-12-1510 minVJHemOnc PodcastiwCLL 2023: The role of continuous BTKis, approaching Richter’s transformation & addressing the underrepresentation of elderly patients in trialsThe biennial International Workshop on Chronic Lymphocytic LeukemiaTM (iwCLL 2023) was held recently in Boston, MA, and brought together experts who shared the latest updates in the treatment and management of CLL.
Tune in as we share some key highlights from this year’s meeting. In this podcast, a variety of topics are covered, including the role of continuous BTK inhibitors (BTKis) in CLL, the importance of investigating the biology of Richter’s transformation (RT), and the need to address the underrepresentation of elderly patients in CLL clinical trials. You will hear from several leading experts, including Kerry Roger...2023-12-0720 minVJHemOnc PodcastiwNHL 2023 Session IV: Novel therapies in NHL: BTK inhibitors, BTK degraders, and bispecific antibodiesThe 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as they discussed the latest clinical updates in the field. In this podcast series, you will hear the latest advances in the treatment and management of lymphoma and gain an insight into the sessions that took place at this year’s meeting.
In this podcast, Tanya Siddiqi, MD, City of Hope, Duarte, CA, and Nirav Shah, MD, Medical College of Wisconsin, Milwaukee, WI, discuss the role of BTK inhibitors and degraders in NHL. Following this, you will hear from Ma...2023-12-0115 minVJHemOnc PodcastUnmet needs in AL amyloidosis, novel treatment strategies being explored, and the role of CHIPIn recent years, there have been promising therapeutic advances in light chain (AL) amyloidosis, however, several unmet needs remain in this disease. Early and accurate diagnosis present a key challenge, and both clinicians and researchers are investigating novel strategies with the aim of improving outcomes for patients.
In this podcast, Angela Dispenzieri, MD, Mayo Clinic, Rochester, MN, Paolo Lopedote, MD, St Elizabeth’s Medical Center, Boston, MA, Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, and Efstathios Kastritis, MD, University of Athens, Athens, Greece, discuss unmet needs in AL amyloidosis, as well as novel immunotherapy st...2023-11-2412 minVJHemOnc PodcastiwNHL 2023 Session III: Recent updates with the use of antibody-drug conjugates in NHLThe 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as they discussed the latest clinical updates in the field. In this podcast series, you will hear the latest advances in the treatment and management of lymphoma and gain an insight into the sessions that took place at this year’s meeting.
In this podcast, John Gribben, MD, DSc, FRCPath, FRCP, FMedSci, Barts Cancer Institute, London, UK, Laurie Sehn, MD, University of British Columbia, Vancouver, Canada, Andrew Davies, MRCP, PhD, University of Southampton, Southampton, UK, and Sven De Vos, MD...2023-11-1716 minVJHemOnc PodcastMPN diagnosis & treatment: novel agents in PV, clinical guidance for the use of JAK inhibitors & the growing role of combination approachesThe treatment and management of myeloproliferative neoplasms (MPNs) including myelofibrosis (MF) and polycythemia vera (PV) has transformed in recent years, although several challenges remain. There are ongoing clinical trials investigating the safety and efficacy of novel agents for this group of diseases, as well as strategies to improve the diagnosis and risk stratification of patients.
In this podcast, Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Anthony Hunter, MD, Winship Cancer Institute of Emory University, Atlanta, GA, Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, and John Mascarenhas, MD...2023-11-1012 minVJHemOnc PodcastiwNHL 2023 Session II: The evolving treatment landscape in mantle cell lymphomaThe 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as they discussed the latest clinical updates in the field. In this podcast series, you will hear the latest advances in the treatment and management of lymphoma and gain an insight into the sessions that took place at this year’s meeting.
In this podcast, Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, Marek Trněný, MD, PhD, Charles University, Prague, Czech Republic, John Kuruvilla, MD, Princess Margaret Cancer Centre, Toronto, Canada, and Yucai Wang, MD, PhD, Mayo Clinic, Roch...2023-11-0314 minVJHemOnc PodcastiwNHL 2023 Session I: Updates on the biology and treatment of T-cell lymphomaThe 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as they discussed the latest clinical updates in the field. In this podcast series, you will hear the latest advances in the treatment and management of lymphoma and gain an insight into the sessions that took place at this year’s meeting.
In this podcast, Francine Foss, MD, Yale School of Medicine, New Haven, CT, Laurence de Leval, MD, PhD, Lausanne University Hospital, Lausanne, Switzerland, Francois Lemonnier, MD, PhD, Henri Mondor University Hospital, Créteil, France, and Steven Horwitz, MD...2023-10-2713 minVJHemOnc PodcastiwAL 2023 Session IV: Transplantation and immunotherapies in AML: improving patient outcomesThe 5th International Workshop on Acute Leukemias (iwAL 2023) took place in San Diego, CA, and brought together leading experts in acute myeloid leukemia (AML) as they discussed the latest updates in the field. In this podcast series, you will hear the latest advances in AML and gain an insight into the sessions that took place at this year’s meeting.
In this podcast, Charles Craddock, CBE, FRCP(UK), FRCPath, DPhil, University of Birmingham, Birmingham, UK, David Sallman, MD, Moffitt Cancer Center, Tampa, FL, Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, and Nelli Bejanyan, MD...2023-10-2014 minVJHemOnc PodcastClassifying frailty and approaching elderly patients with lymphomaWhile the treatment landscape of both Hodgkin and non-Hodgkin lymphoma (HL; NHL) has improved in recent years, there are several challenges associated with treating elderly patients in these disease settings. The presence of comorbidities, as well as the risk of treatment-related toxicities, makes the treatment of elderly patients an important area of research.
In this podcast, Pallawi Torka, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, and Jonathan Friedberg, MD, MMSc, University of Rochester, Rochester, NY, discuss challenges with classifying frailty in elderly patients with diffuse large B-cell lymphoma (DLBCL) and HL, as well as...2023-10-1311 minVJHemOnc PodcastUpdates on the diagnosis, risk stratification and treatment of lower-risk MDSThe treatment and management of lower-risk myelodysplastic syndromes (LR-MDS) has remained a challenge in the field, and several studies are being conducted with the goal of improving the understanding of this disease. Furthermore, there have been recent updates to classification systems for MDS, including the Molecular International Prognostic Scoring System (IPSS-M).
In this podcast, you will hear from Sanam Loghavi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Rami Komrokji, MD, Moffitt Cancer Center, Tampa, FL, who discuss recent updates in the diagnosis, risk stratification and treatment of LR-MDS. This discussion was filmed...2023-10-0619 minVJHemOnc PodcastiwAL 2023 Session III: The relevance of TP53 mutation in AMLThe 5th International Workshop on Acute Leukemias (iwAL 2023) took place in San Diego, CA, and brought together leading experts in acute myeloid leukemia (AML) as they discussed the latest updates in the field. In this podcast series, you will hear the latest advances in AML and gain an insight into the sessions that took place at this year’s meeting.
In this podcast, Andrew Wei, MBBS, PhD, Peter MacCallum Cancer Centre and the Royal Melbourne Hospital, Melbourne, Australia, and Sanam Loghavi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discuss the relevance of TP53 mu...2023-09-2909 minVJHemOnc PodcastiwAL 2023 Session II: Novel treatments in AML: FLT3 inhibitors, combinations, and more
The 5th International Workshop on Acute Leukemias (iwAL 2023) took place in San Diego, CA, and brought together leading experts in acute myeloid leukemia (AML) as they discussed the latest updates in the field. In this podcast series, you will hear the latest advances in AML and gain an insight into the sessions that took place at this year’s meeting.
In this podcast, Naval Daver, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Gail Roboz, MD, Weill Cornell Medicine, New York City, NY, Harry Erba, MD, PhD, Duke University, Durham, NC, and Jessica Altman, MD...2023-09-2228 minVJHemOnc PodcastiwAL 2023 Session I: Clonal hematopoiesis in AML, early detection and potential therapeuticsThe 5th International Workshop on Acute Leukemias (iwAL 2023) took place in San Diego, CA, and brought together leading experts in acute myeloid leukemia (AML) as they discussed the latest updates in the field. In this podcast series, you will hear the latest advances in AML and gain an insight into the sessions that took place at this year’s meeting.
In this podcast, Ravi Majeti, MD, PhD, Stanford University, Stanford, CA, Courtney DiNardo, MD, MSCE, The University of Texas MD Anderson Cancer Center, Houston, TX, Uma Borate, MBBS, The Ohio State University Comprehensive Cancer Center, Columbus, OH, an...2023-09-1518 minVJHemOnc PodcastApplications of MRD in multiple myeloma: using MRD to guide treatment decisionsMeasurable residual disease (MRD) has become a key biomarker in the field of multiple myeloma (MM), and the sensitivity of MRD testing has increased in recent years. MRD can indicate the depth of response to treatment as well as patient outcomes, leading to suggestions of using MRD status to guide the treatment of patients with myeloma.
In this podcast, you will hear from Meral Beksac, MD, Ankara University, Ankara, Turkey, Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, and Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, who discuss the exciting potential applications of MRD...2023-09-0810 minVJHemOnc PodcastExploring and comparing the curative potential of CAR-T therapy & bispecific antibodies in R/R DLBCLThe treatment and management of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) remains a major unmet need, and in recent years, the introduction of immunotherapies including CAR-T cells and bispecific antibodies has provided hope for several patients.
While both CAR-T cells and bispecific antibodies have their benefits, there are several factors to consider when evaluating their curative potential in R/R DLBCL. In this podcast, you will hear from Manali Kamdar, MD, University of Colorado, Aurora, CO, Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, and Gloria Iacoboni, MD...2023-08-2309 minVJHemOnc PodcastPre-MDS states: improving prognosis, novel therapeutic approaches, and challenges with distinguishing these conditionsMyelodysplastic syndromes (MDS) represent a heterogeneic group of disorders which remain a challenge to diagnose and treat. In recent years, there has been an increased interest in understanding various pre-MDS states, including idiopathic cytopenia of unknown significance (ICUS), clonal hematopoiesis of indeterminate potential (CHIP), and clonal cytopenia of unknown significance (CCUS). The identification and classification of these pre-MDS states remains a challenge in the field, and it is important to continue developing distinct criteria to distinguish between these states and overt disease.
In this podcast, you will hear from Moshe Mittelman, MD, Tel Aviv Sourasky Medical Center...2023-08-1610 minVJHemOnc PodcastAccelerated-phase MPNs: mutational landscape, challenges, and novel treatment strategies being exploredPatients with BCR-ABL negative myeloproliferative neoplasms (MPNs) are at risk of progressing to accelerated-phase or blast-phase disease (MPN-AP/BP). Several mutations, including ASXL1, EZH2, and TP53, are involved in progression to MPN-AP/BP, and there are a number of challenges with treating patients who progress to this stage.
In this podcast, Anand Patel, MD, University of Chicago, Chicago, IL, Andrew Kuykendall, MD, Moffitt Cancer Center, Tampa, FL, and Jan Philipp Bewersdorf, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, discuss the mutational landscape of MPN-AP, and further highlight challenges with treating patients. The experts also com...2023-08-1008 minVJHemOnc PodcastDetermining the optimal sequencing of bispecifics and CAR-T cells in multiple myelomaBispecific antibodies and CAR-T cells have transformed the myeloma treatment landscape in recent years, providing hope for patients with relapsed/refractory (R/R) disease. While both of these therapies offer benefits to patients, there are challenges to address regarding the optimal sequencing of these agents.
In this podcast, experts Salomon Manier, MD, PhD, Lille University Hospital, Lille, France, Surbhi Sidana, MD, Stanford University, Stanford, CA, and Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, share some interesting insights into the optimal sequencing of bispecific antibodies and CAR-T cells in myeloma, highlighting data from recent cl...2023-08-0307 minVJHemOnc PodcastOvercoming barriers to CAR-T therapy: improving access and costCAR-T therapy has become a promising novel option for patients with relapsed/refractory (R/R) hematological malignancies, providing hope to several individuals with a high unmet medical need. Although CAR-T cells have demonstrated promising efficacy in patients, there are several challenges that need to be overcome before these are optimally used in clinical practice.
In this podcast, you will hear from Edward Cliff, MPH, MBBS, Brigham and Women’s Hospital, Boston, MA, and Natacha Bolaños, Lymphoma Coalition Europe, Madrid, Spain, who discuss two major barriers to CAR-T therapy: the high cost of CAR-T cells and the nee...2023-07-2711 minVJHemOnc PodcastThe importance of addressing quality of life and improving symptom management in MPNsMyeloproliferative neoplasms (MPNs) represent a challenging group of diseases to treat, and patients with MPNs suffer from several symptoms which negatively impact their quality of life (QoL). Novel agents, including JAK inhibitors, have demonstrated an ability to reduce symptom burden in patients with MPNs, and there is ongoing research aimed at improving symptom management and QoL in these patients.
In this podcast, you will hear from Ruben Mesa, MD, Levine Cancer Institute, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, NC, Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and...2023-07-1906 minVJHemOnc PodcastUpdates in the treatment and management of amyloidosis and the importance of the multidisciplinary teamAmyloidosis is a rare disease in which insoluble amyloid proteins are deposited in tissues or organs, resulting in organ damage. The diagnosis and treatment of this disease remain a major challenge, with several novel agents being explored in clinical trials. Furthermore, clinicians and researchers are drawing attention to the important role of the multidisciplinary team (MDT) in the treatment and management of patients.
In this podcast, experts Meral Beksac, MD, Ankara University, Ankara, Turkey, Shaji Kumar, MD, Mayo Clinic, Rochester, MN, and Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, discuss recent updates in...2023-07-1108 minVJHemOnc PodcastHigh-risk MDS: unmet needs and future treatment approachesMyelodysplastic syndromes (MDS) represent a heterogeneous group of myeloid neoplasms, and the treatment and management of high-risk MDS remains a challenge. With only two agents currently approved by the FDA and available to patients with high-risk disease, several experts agree that novel therapeutic strategies should be explored. Many ongoing clinical trials are evaluating the safety and efficacy of combination therapies, with the aim of providing more hope for patients and overcoming challenges in the field.
In this exclusive podcast, you will hear from leading experts Uwe Platzbecker, MD, University of Leipzig, Leipzig, Germany, Naval Daver, MD, University...2022-08-1907 minVJHemOnc PodcastFocus on ALL: treating older patients, Ph-like ALL & post-transplant interventionsAdvances in both the treatment landscape and the pathology of the disease have improved the outcome of children and adults with acute lymphoblastic leukemia (ALL). However, many challenges still remain, including the treatment of older patients with ALL, diagnosis of Philadelphia chromosome-like (Ph-like) ALL, a newly identified aggressive subtype, as well as the evolving role of hematopoietic stem cell transplantation.
In this exclusive podcast, VJHemOnc spoke with Selina Luger, MD, of the University of Pennsylvania, Philadelphia, PA, Sarah Tasian, MD, from The Children’s Hospital of Philadelphia, Philadelphia, PA and David Marks, MBBS, PhD, FRACP, FRCPath, of th...2021-05-2809 minVJHemOnc PodcastThe Myeloma Sessions: Post-ASH 2020 UK DiscussionThe development of immunomodulatory agents and proteasome inhibitors alongside stem cell transplantation and chemotherapy has significantly improved the treatment options for patients with myeloma. Recently, B-cell maturation antigen (BCMA) has emerged as a promising target for myeloma treatment due to its selective expression in malignant plasma cells. Current work in this area focuses on determining the optimal combination of therapies, treatment strategies to overcome relapse, and clinical trials to aid the development of novel BCMA-targeted treatment modalities.
VJHemOnc is joined by Rakesh Popat, MBBS, MRCP, FRCPath, PhD, of University College London Hospitals NHS Foundation Trust, London, UK...2021-04-1943 minVJHemOnc PodcastPost-ASH Amyloidosis Session from VJHemOncThe most common form of amyloidosis, light-chain (AL) amyloidosis, results from abnormalities in plasma cells causing them to produce abnormal amyloid fibrils made up of immunoglobulin light chains. These insoluble fibrils deposit extracellularly and accumulate within organs such as the heart, kidneys, liver, spleen, nervous system, and digestive tract, disrupting their structure and impairing their function. Historically, successful treatments for amyloidosis have been anti-plasma cell chemotherapies that reduce the production of amyloidogenic light chains. More recently, monoclonal antibody treatments such as daratumumab, evaluated in the ANDROMEDA trial, have demonstrated efficacy against malignant plasma cells. Current investigations are also exploring...2021-04-1332 minVJHemOnc PodcastThe Post-EBMT VJSessions from VJHemOncThe 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) was held virtually this year and showcased the latest advances in the field of transplantation and cellular therapies.
VJHemOnc is joined by Christian Chabannon, MD, PhD, Institut Paoli Calmettes, Marseille, France, who chaired an insightful discussion on the main takeaways from the EBMT 2021 meeting, including trial updates in conditioning, novel approaches to managing graft-versus-host disease, the role of transplantation in rarer hematological malignancies and the latest news in immune effector cell therapies.
In this roundtable discussion, Prof. Chabannon is joined by...2021-04-0735 minVJHemOnc PodcastThe MDS Sessions: Giants in MDSThe diagnosis and treatment of myelodysplastic syndromes (MDS) has moved on dramatically in the few three decades. From across the globe, pioneers in the recognition and understanding of MDS pulled together to collaborate and push forward this research laying the foundations of where we are today.
VJHemOnc were delighted to catch up with four of these pioneers to discuss their research – taking us from inception to future outlooks. Chaired by Amer Zeidan, MBBS, MHS, Yale University School of Medicine and Yale Cancer Center, New Haven, CT, this roundtable discussion included a prestigious panel in the world of MD...2021-03-171h 09VJHemOnc PodcastMyeloma at ASH 2020: talquetemab, CARTITUDE-1 & highlightsThe field of multiple myeloma is rapidly evolving and can be credited to an increased understanding of the biology of the disease leading to an improvement in patients outcomes. Despite vast advances, the clinical management of patients with multiple myeloma remains challenging, namely resistance in relapsed patients as well as the identification of predictive and prognostic biomarkers.
In this podcast following the virtual annual American Society of Hematology (ASH) 2020 meeting, we hear from three leading experts in multiple myeloma, Niels van de Donk of the UV University Medical Center, Amsterdam, Netherlands, Yi Lin of Mayo Clinic, Rochester...2021-01-2013 minVJHemOnc PodcastSystemic mastocytosis: current landscape, novel agents and COVID-19Systemic mastocytosis (SM) is a rare hematological neoplasm. Advanced systemic mastocytosis can be sub-classified into either aggressive SM, SM with an associated hematological neoplasm (SM-AHN) or mast cell leukemia.
In this insightful podcast, Deepti Radia, MBBS, MRCPI, FRCPath, of Guy’s and St Thomas’ Hospital NHS Foundation Trust, London UK, firstly discusses the management of patients with systemic mastocytosis with associated hematological neoplasm. Dr Radia also details the current treatment options for this condition, as well as on-going clinical trials. Additionally, Dr Radia discusses the management of hematological oncology patients during the COVID-19 pandemic.
This interview was...2020-06-0208 min